Your session is about to expire
← Back to Search
Envarsus XR for Kidney Transplant (EnvarsusXR Trial)
EnvarsusXR Trial Summary
This trial is testing if a once-daily oral tacrolimus formulation is better than the current twice-daily tacrolimus formulation in adolescent organ transplant recipients.
- Kidney Transplant
EnvarsusXR Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.EnvarsusXR Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
For what type of volunteers is this clinical trial best suited?
"This clinical trial is recruiting 28 eligible participants, aged between 13 and 20, that have undergone a successful kidney transplant. In addition to age constraints, applicants must be currently receiving the same dosage of tacrolimus and mycophenolate mofetil (MMF) or enteric-coated mycophenolic acid (EC-MPA) for at least six months prior with no greater than 0.5mg/dose alterations in the last four months. Lastly, it is imperative to note that all enrolled patients should remain compliant with study protocols throughout its duration."
Does the inclusion criteria allow for participants over 55 years of age?
"Eligible participants for this medical trial must be at least 13 years old but no older than 20."
Are there any vacancies available for individuals interested in participating in this research?
"This trial is presently in a inactive state, with the original posting on January 15th 2019 and last edit occurring April 15th of this year. If you are curious about other studies that may be seeking participants, there are currently 85 medical trials for kidney related issues as well as 150 utilizing Envarsus XR medication."
How many volunteers are participating in this experimental research?
"This clinical trial has closed enrollment. It was first posted on January 15th, 2019 and last edited on April 15th, 2019. In the event you are looking for other medical trials to join, there are presently 85 studies involving kidney-related issues as well as 150 Envarsus XR trials actively recruiting patients."
What ailments would a doctor typically recommend Envarsus XR for?
"Envarsus XR offers a potential solution for those suffering from dermatitis, atopic conditions, and organ rejection following liver or kidney transplantation."
What are the known safety profiles of Envarsus XR for patients?
"The approved status of Envarsus XR allows us to confidently rate its safety as a 3 on our scale."
What past experiments apply to Envarsus XR's therapeutic efficacy?
"At this time, 150 clinical trials are active for Envarsus XR. Of those studies, 18 have reached Phase 3 while the remaining ones remain in earlier stages of research. The majority of these tests take place at sites based out of Nashville but 871 other locations around the world are also running such trials."
Share this study with friends
Copy Link
Messenger